Investigating gene expression changes and therapeutic strategies in colorectal cancer, indicating miR-595's role in chemoresistance.
MicroRNAs (miRNAs) are critical post-transcriptional regulators of gene expression and play key roles in cancer progression and chemoresistance. In this study, we investigated the expression profiles of selected cancer-associated miRNAs in response to two chemotherapeutic agents, docetaxel and lapatinib, in colorectal cancer cell lines. We also explored the potential regulatory interaction between miR-595 and the oncogene E2F7. Colorectal cancer cells (HT-29 and HCT-116) were treated with the IC₅₀ concentrations of docetaxel and lapatinib. RT-qPCR analysis revealed that docetaxel treatment significantly upregulated miR-718, miR-206, miR-1199, and miR-595 in HT-29 cells. In contrast, only miR-206 was upregulated, while the other genes were downregulated in HCT-116 cells. Lapatinib moderately increased the expression of the selected miRNAs in HT-29 cells but consistently downregulated all four miRNAs in HCT-116 cells. Bioinformatic analysis using TargetScan identified E2F7 as a potential target of miR-595. E2F7 expression was found to be elevated in colorectal cancer and further increased in docetaxel-treated HT-29 cells, suggesting a role in drug resistance. Overexpression of miR-595 resulted in the downregulation of E2F7, supporting a regulatory interaction. These findings suggest that miR-595 negatively regulates E2F7 and may contribute to modulating chemoresistance in colorectal cancer. Targeting the miR-595/E2F7 axis may offer a novel therapeutic strategy to enhance the efficacy of chemotherapy in colorectal cancer treatment.
No takes yet. Share an insight, caveat, or question.
Noaman et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: